Understanding therapeutic targets in thrombotic thrombocytopenic purpura

Understanding therapeutic targets in thrombotic thrombocytopenic purpura Intensive Care Med (2017) 43:1398–1400 DOI 10.1007/s00134-016-4662-3 UNDERSTANDING THE DISEASE Understanding therapeutic targets in thrombotic thrombocytopenic purpura 1 2 1* Bérangère S. Joly , Karen Vanhoorelbeke and Agnès Veyradier © 2017 Springer-Verlag Berlin Heidelberg and ESICM Thrombotic thrombocytopenic purpura (TTP) is a rare and multiple organ failure [5, 6]. The mechanism of thrombotic microangiopathy specifically related to a severe ADAMTS13 deficiency is acquired in the large severe functional deficiency of the von Willebrand factor majority of cases and is related to the presence of anti- (VWF) cleaving protease, ADAMTS13 (a disintegrin and ADAMTS13 auto-antibodies (auto-Abs). In some rare metalloprotease with thrombospondin type 1 repeats, cases, ADAMTS13 deficiency is inherited, and is linked member 13) [1, 2]. VWF is a multimeric plasma glyco- to the presence of bi-allelic recessive mutations in the protein of which the monomers, containing multiple ADAMTS13 gene [1–3, 5–8]. Whatever the acquired or functional domains, are connected by disulfide bonds [ 3]. hereditary etiology of TTP, its time course is character- In cases of vascular injury, VWF contributes to the initial ized by a relapsing tendency. Acute TTP remains a severe recruitment of platelets to the injured vessel wall and to and life-threatening disease, but treatments, most http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Intensive Care Medicine Springer Journals

Understanding therapeutic targets in thrombotic thrombocytopenic purpura

Loading next page...
 
/lp/springer_journal/understanding-therapeutic-targets-in-thrombotic-thrombocytopenic-IKOQ6fnwc0
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg and ESICM
Subject
Medicine & Public Health; Intensive / Critical Care Medicine; Anesthesiology; Emergency Medicine; Pneumology/Respiratory System; Pain Medicine; Pediatrics
ISSN
0342-4642
eISSN
1432-1238
D.O.I.
10.1007/s00134-016-4662-3
Publisher site
See Article on Publisher Site

Abstract

Intensive Care Med (2017) 43:1398–1400 DOI 10.1007/s00134-016-4662-3 UNDERSTANDING THE DISEASE Understanding therapeutic targets in thrombotic thrombocytopenic purpura 1 2 1* Bérangère S. Joly , Karen Vanhoorelbeke and Agnès Veyradier © 2017 Springer-Verlag Berlin Heidelberg and ESICM Thrombotic thrombocytopenic purpura (TTP) is a rare and multiple organ failure [5, 6]. The mechanism of thrombotic microangiopathy specifically related to a severe ADAMTS13 deficiency is acquired in the large severe functional deficiency of the von Willebrand factor majority of cases and is related to the presence of anti- (VWF) cleaving protease, ADAMTS13 (a disintegrin and ADAMTS13 auto-antibodies (auto-Abs). In some rare metalloprotease with thrombospondin type 1 repeats, cases, ADAMTS13 deficiency is inherited, and is linked member 13) [1, 2]. VWF is a multimeric plasma glyco- to the presence of bi-allelic recessive mutations in the protein of which the monomers, containing multiple ADAMTS13 gene [1–3, 5–8]. Whatever the acquired or functional domains, are connected by disulfide bonds [ 3]. hereditary etiology of TTP, its time course is character- In cases of vascular injury, VWF contributes to the initial ized by a relapsing tendency. Acute TTP remains a severe recruitment of platelets to the injured vessel wall and to and life-threatening disease, but treatments, most

Journal

Intensive Care MedicineSpringer Journals

Published: Jan 23, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off